mocravimod
FDA Grants Fast Track Designation for Mocravimod in Combination with HSCT for AML
Leah SherwoodAcute Myeloid Leukemia | November 14, 2022
Mocravimod is a synthetic, sphingosine 1-phosphate receptor modulator that has been assessed in phase I and II trials.
Read More
S1PR Modulator Mocravimod Granted Fast Track Designation
Leah LawrenceAcute Myeloid Leukemia | February 2, 2023
Mocravimod is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator.
Read More
Advertisement
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    © 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |